Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Disruption of methionine metabolism drives erythroid cell fate reprogramming by remodeling the H3K4me3 landscape
Lei Sun, Hengchao Zhang, Mengjia Li, Quande Lin, Xiuyun Wu, Ying Cheng, Shihui Wang, Yan Hou, Yaomei Wang, Yue Sheng, Jing Liu, Xiuli An, Ting Wang, Lixiang Chen
Lei Sun, Hengchao Zhang, Mengjia Li, Quande Lin, Xiuyun Wu, Ying Cheng, Shihui Wang, Yan Hou, Yaomei Wang, Yue Sheng, Jing Liu, Xiuli An, Ting Wang, Lixiang Chen
View: Text | PDF
Research Article Cell biology Hematology

Disruption of methionine metabolism drives erythroid cell fate reprogramming by remodeling the H3K4me3 landscape

  • Text
  • PDF
Abstract

The methionine cycle plays critical roles in cell fate determination by shaping epigenetic landscape, yet its function in human erythropoiesis remains undefined. Here, we show that disruption of methionine metabolism by compromising the key enzyme adenosylhomocysteinase (AHCY) reshapes H3K4me3 landscape, causing erythroid cell fate reprogramming. AHCY deficiency severely impaired erythroid differentiation and expansion, leading to the generation of nonerythroid lineage hematopoietic cells, including stem/progenitor cells and immune cells, as evidenced by single-cell RNA-seq, and pseudo temporal analysis delineated a precise dedifferentiation trajectory, revealing erythroblasts transitioning back to MEPs and HSCs. Moreover, the human hematopoietic system could be reconstituted in the immunodeficient NCG-X mice by transplanting AHCY-deficient erythroblasts. Mechanistically, AHCY deficiency reduced global H3K4me3 levels and altered its genomic distribution, resulting in the upregulated expression of nonerythroid transcription factors and downregulated expression of erythrocyte lineage-specific transcription factors. Integrated single-cell analyses identified transitional states with diminished AHCY in the erythroblasts of a patient with acute myeloid leukemia (AML). Further flow cytometry confirmed the reduced H3K4me3 level in patient-derived erythroid cells. Erythroblasts isolated from patients with AML with reduced H3K4me3 exhibited a dedifferentiation potential into progenitor-like states. Our findings reveal a metabolic-epigenetic axis governing cell fate reprogramming in human erythropoiesis and provide insights into leukemia-associated anemia.

Authors

Lei Sun, Hengchao Zhang, Mengjia Li, Quande Lin, Xiuyun Wu, Ying Cheng, Shihui Wang, Yan Hou, Yaomei Wang, Yue Sheng, Jing Liu, Xiuli An, Ting Wang, Lixiang Chen

×

Figure 3

Reconstitution of Human hematopoietic in immunodeficient mice after transplantation of AHCY-deficient erythroid cells.

Options: View larger image (or click on image) Download as PowerPoint
Reconstitution of Human hematopoietic in immunodeficient mice after tran...
(A) Schematic of the experimental protocol for transplanting DZNep-treated proerythroblasts into NCG-X mice and evaluating hematopoietic lineage reconstitution. (B) Flow cytometry analysis of BM 4 and 12 weeks after transplantation for determination of human engraftment rates, including DMSO, positive control, and DZNep groups. (C) Quantitative analysis of human CD45+ cells in BM from 3 independent mice 4 weeks after transplantation. (D) Quantitative analysis of human CD45+ cells in BM from 5 independent mice 12 weeks after transplantation. (E) Flow cytometry analysis of spleen cells 4 and 12 weeks after transplantation for determination of human engraftment rates including DMSO, positive control, and DZNep groups. (F) Quantitative analysis of the percentage of human CD45+ cells of spleens from 3 independent mice 4 weeks after transplantation. (G) Quantitative analysis of the percentage of human CD45+ cells of spleens from 5 independent mice 12 weeks after transplantation. (H) Flow cytometry analysis of PB 4 and 12 weeks after transplantation for determination of human engraftment rates including DMSO, positive control, and DZNep groups. (I) Quantitative analysis of the percentage of human CD45+ cells of PB from 3 independent mice 4 weeks after transplantation. (J) Quantitative analysis of the percentage of human CD45+ cells of PB from 5 independent mice 12 weeks after transplantation. (K) UMAP visualization of all human- and mouse-derived cells displayed with different colors for clusters. (L) UMAP visualization of all human-derived cells displayed with different colors for clusters after reannotation. (M) Dot plots indicate gene expressions in each subcluster. (N) Pie chart illustrates the proportional distribution of each cell subpopulation. Statistical analysis is from 3 or 5 independent experiments *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts